Monopar director plans sale of 6,284 shares
Monopar Therapeutics (MNPR) has a notice from director Raymond William Anderson to sell shares of its common stock under Rule 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) has a notice from director Raymond William Anderson to sell shares of its common stock under Rule 144. The notice covers 6,284 shares of common stock, to be received and sold upon the exercise of stock options over a three‑month period, with trades listed for NASDAQ and handled through Morgan Stanley Smith Barney LLC. The securities will be paid for in cash, and the stated date associated with the proposed sale is 08/25/2026.
Key Figures
Key Terms
Rule 144 regulatory
Form 144 regulatory
exercise of stock options financial
securities to be sold financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing mean for Monopar Therapeutics (MNPR)?
What is the key date mentioned in the Monopar Therapeutics (MNPR) Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.